SCHEMBL19637165

SCHEMBL19637165

CCc1c(C)nc(OCCCN2CCOCC2)nc1N(CC)CC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 3/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CHRM2 P08172 1/20 0.45
▸ CHRM1 P11229 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ SCN1A P35498 1/20 0.45
▸ HTR2B P41595 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ SCN2A Q99250 1/20 0.45
▸ SIGMAR1 Q99720 1/20 0.45
▸ SCN3A Q9NY46 1/20 0.45
▸ USP2 O75604 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CYP2D6 P10635 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TLR7 Q9NYK1 4/20 0.40
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19636917 0.88 HRH3 (0.42) HRH3ALDH1A1KCNH2SIGMAR1
SCHEMBL19637387 0.75 HTR2A (0.43) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL22994841 0.74 KDM4E (0.38) HRH3ALDH1A1CYP1A2CYP2D6CYP3A4
SCHEMBL21895740 0.73 ALDH1A1 (0.41) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL19637369 0.73 HTT (0.35) CYP1A2HTT
SCHEMBL22994789 0.72 KRAS (0.44) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL1603001 0.68 NPC1 (0.44) ALDH1A1KCNH2SIGMAR1TSHRKDM4E
SCHEMBL22994702 0.67 ALDH1A1 (0.41) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL21895570 0.67 MAPK1 (0.41) HRH3MAPK1ALDH1A1CYP1A2CHRM2
SCHEMBL13937523 0.65 CYP2D6 (0.53) HRH3MAPK1ALDH1A1CYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
WO-2020055755-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2020-03-19 — — WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
Send feedback